HBM Healthcare Investments AG (0QOC.L) LSE
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In CHF
Sector
Financial Services
Industry
Asset Management
Employees
N/A
First IPO Date
March 20, 2014
| Name | Title | Pay | Year Born |
| Andreas Wicki | Chief Executive Officer | 172,461 | 1958 |
| Erwin Troxler | Chief Financial Officer | 104,000 | 1970 |
| Benedikt Suter | Secretary to the Board of Directors | 0 | 1964 |
| Thomas Thaler | Advisor of HBM Partners | 0 | N/A |
| Alexander G. Asam | Investment Advisor | 0 | 1966 |
HBM Healthcare Investments AG strategically deploys capital through both direct investments and allocations to other funds, targeting middle-market and mature companies. Its investment mandate is broad, encompassing various stages from nascent startups, early-stage, mid-stage, and late-stage private ventures to emerging unlisted businesses, smaller public companies, management buyouts, growth capital opportunities, and private investments in public equities (PIPEs). Within its fund-of-funds segment, it specifically backs venture capital funds. The firm also provides financing for the spin-off of product lines or departments from larger corporations, supports the expansion or restructuring of established businesses, and participates in seed, venture, and expansion capital rounds, along with additional buyout transactions. HBM's primary focus is on private and public entities within the healthcare sector, with a strong emphasis on human medicine, pharmaceuticals (including biopharma), biotechnology, diagnostics, medical technology, and related industries. Initial investments are typically made in companies whose core products are either in clinical development or the stage immediately preceding it. The fund adopts a global investment approach, concentrating its efforts particularly on the Asia Pacific region, North America, and Europe. For publicly listed companies, HBM generally targets those that have transitioned from its private investment portfolio. The firm often increases its stake in portfolio companies by participating in subsequent financing rounds or after the company's initial public offering. HBM may acquire controlling interests in portfolio companies and frequently secures a seat on their Board of Directors. While equity investments are its predominant method, it also utilizes a range of other financial instruments, including convertible bonds, debt securities, structured products, and derivatives. HBM's primary exit strategies for its portfolio companies involve trade sales or initial public offerings.